{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:33:08Z","timestamp":1773387188508,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1053\/j.seminoncol.2011.04.015","type":"journal-article","created":{"date-parts":[[2011,9,23]],"date-time":"2011-09-23T17:52:12Z","timestamp":1316800332000},"page":"648-657","source":"Crossref","is-referenced-by-count":12,"title":["Role of Lenalidomide in the Treatment of Myelodysplastic Syndromes"],"prefix":"10.1053","volume":"38","author":[{"given":"Rami S.","family":"Komrokji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan F.","family":"List","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2011.04.015_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.hoc.2010.02.004","article-title":"Myelodysplastic syndromes classification and risk stratification","volume":"24","author":"Komrokji","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib2","first-page":"2535","article-title":"Disparities in criteria for initiating chelation therapy for iron overload in patients with myelodysplastic syndromes (MDS)","volume":"106","author":"Bennett","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/asheducation-2007.1.398","article-title":"Management of RBC-transfusion dependence","volume":"1","author":"Melchert","year":"2007","journal-title":"Hematology (Amsterdam)"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hoc.2010.02.013","article-title":"Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions","volume":"24","author":"Komrokji","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nature Rev Cancer"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/368126","article-title":"Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro","volume":"187","author":"Haslett","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2249.1995.tb05527.x","article-title":"The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures","volume":"99","author":"Mchugh","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib10","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.4049\/jimmunol.168.10.4914","article-title":"Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity","volume":"168","author":"Dredge","year":"2002","journal-title":"J Immunol (Baltimore)"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib12","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0162-3109(95)00050-X","article-title":"Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade","volume":"31","author":"Geitz","year":"1996","journal-title":"Immunopharmacology"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/cncr.22047","article-title":"Thalidomide therapy in adult patients with myelodysplastic syndrome","volume":"107","author":"Moreno-Aspitia","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2141.2005.05817.x","article-title":"A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies","volume":"131","author":"Bouscary","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib17","first-page":"884","article-title":"Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes","volume":"87","author":"Musto","year":"2002","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2402330","article-title":"Thalidomide for the treatment of patients with myelodysplastic syndromes","volume":"16","author":"Strupp","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.leu.2402894","article-title":"Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome","volume":"17","author":"Strupp","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2011.04.015_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/107327480601304s02","article-title":"Lenalidomide: targeted anemia therapy for myelodysplastic syndromes","volume":"13","author":"List","year":"2006","journal-title":"Cancer Control"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/251437a0","article-title":"Distinct haematological disorder with deletion of long arm of no. 5 chromosome","volume":"251","author":"Van Den Berghe","year":"1974","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10245330410001723824","article-title":"The 5q- syndrome","volume":"9","author":"Giagounidis","year":"2004","journal-title":"Hematology (Amsterdam)"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2007.06833.x","article-title":"Gene expression profiling of CD34+ cells in patients with the 5q- syndrome","volume":"139","author":"Boultwood","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm1512","article-title":"Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation","volume":"13","author":"Liu","year":"2007","journal-title":"Nature Med"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2007-01-068809","article-title":"Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders","volume":"110","author":"Joslin","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q- syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ymgme.2006.11.004","article-title":"The functions of RPS19 and their relationship to Diamond-Blackfan anemia: a review","volume":"90","author":"Morimoto","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/459046a","article-title":"Cell biology: arrest by ribosome","volume":"459","author":"Ferreira-Cerca","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nm.2063","article-title":"A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome","volume":"16","author":"Barlow","year":"2010","journal-title":"Nature Med"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm.2054","article-title":"Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype","volume":"16","author":"Starczynowski","year":"2010","journal-title":"Nature Med"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib32","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2011.04.015_bib33","doi-asserted-by":"crossref","first-page":"s38","DOI":"10.1016\/S0145-2126(07)70066-8","article-title":"Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion","volume":"31","author":"List","year":"2007","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib34","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0145-2126(00)00088-6","article-title":"Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients","volume":"24","author":"Germing","year":"2000","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00277-009-0846-z","article-title":"Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression","volume":"89","author":"Gohring","year":"2010","journal-title":"Ann Hematol"},{"issue":"Suppl","key":"10.1053\/j.seminoncol.2011.04.015_bib36","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1200\/jco.2010.28.15_suppl.6598","article-title":"Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-\/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib37","doi-asserted-by":"crossref","first-page":"12974","DOI":"10.1073\/pnas.0811267106","article-title":"A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide","volume":"106","author":"Wei","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib38","first-page":"292","article-title":"Secondary resistance to lenalidomide in del(5q) MDS is associated with CDC25C & PP2A overexpression","volume":"114","author":"List","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib40","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood.V89.5.1690","article-title":"Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome","volume":"89","author":"Hoefsloot","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib41","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1172\/JCI32322","article-title":"Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells","volume":"118","author":"Moutouh-De Parseval","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib43","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1371\/journal.pmed.0050035","article-title":"An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome","volume":"5","author":"Ebert","year":"2008","journal-title":"PLoS Med"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib44","first-page":"1360","article-title":"Lenalidomide (CC-5013; Revlimid) promotes erythropoiesis in myelodysplastic syndromes (MDS) by CD45 protein tyrosine phosphatase (PTP) inhibition","volume":"108","author":"List","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib45","first-page":"4626","article-title":"Two-stage pharmacokinetic & efficacy study of lenalidomide alone or combined with recombinant erythropoietin (EPO) in lower risk MDS EPO-failures [PK-002]","volume":"110","author":"List","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib46","doi-asserted-by":"crossref","first-page":"902","DOI":"10.6004\/jnccn.2008.0069","article-title":"Myelodysplastic syndromes","volume":"6","author":"Greenberg","year":"2008","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib47","first-page":"820","article-title":"Lenalidomide (LEN) in INT 2 and high risk MDS with DEL 5q","volume":"110","author":"Burcheri","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib48","first-page":"115","article-title":"lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities","volume":"114","author":"Mollgard","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib49","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2009.26.0745","article-title":"Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes","volume":"28","author":"Sekeres","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib50","first-page":"842","article-title":"A phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients > 60 years old","volume":"114","author":"Vij","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib51","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1182\/blood-2008-04-152678","article-title":"Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13","volume":"113","author":"Fehniger","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib52","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2007.15.5770","article-title":"Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes","volume":"26","author":"Sekeres","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib53","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","article-title":"Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia","volume":"115","author":"Pal","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2011.04.015_bib54","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775411001308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775411001308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T15:25:59Z","timestamp":1712935559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775411001308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0093775411001308"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2011.04.015","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}